Subtopic Deep Dive
HLA-B27 and Spondyloarthritis Genetics
Research Guide
What is HLA-B27 and Spondyloarthritis Genetics?
HLA-B27 and Spondyloarthritis Genetics examines the genetic contributions of HLA-B27 and associated variants to spondyloarthritis susceptibility, pathogenesis, and clinical outcomes through association studies and functional analyses.
HLA-B27 confers high risk for ankylosing spondylitis, a core spondyloarthritis subtype, with prevalence studies showing elevated spondyloarthropathy rates in carriers (Braun et al., 1998, 913 citations). Genome-wide studies identify interacting loci like ERAP1 that modulate peptide handling and disease risk (Evans et al., 2011, 885 citations). High-density genotyping reveals multiple immune-related risk variants beyond HLA-B27 (Cortés et al., 2013, 853 citations).
Why It Matters
HLA-B27 prevalence data from blood donor screening enables risk stratification in populations, informing early screening protocols (Braun et al., 1998). ERAP1-HLA-B27 interactions highlight peptide processing pathways as therapeutic targets, guiding biologics development in axial spondyloarthritis (Evans et al., 2011). Multi-locus risk models from genotyping studies support personalized prognosis and trial designs, bridging genetics to clinical management (Cortés et al., 2013). Age-at-onset differences by HLA-B27 status refine diagnostic timelines and patient counseling (Feldtkeller et al., 2003).
Key Research Challenges
ERAP1-HLA-B27 Interaction Mechanisms
Dissecting how ERAP1 variants alter peptide trimming for HLA-B27 influences disease susceptibility via endoplasmic reticulum pathways (Evans et al., 2011). Functional validation requires integrating genetic and proteomic data. Limited models hinder causality proof.
Non-HLA Risk Variant Discovery
High-density genotyping identifies multiple loci, but effect sizes are small and require larger cohorts for replication (Cortés et al., 2013). Distinguishing shared versus ankylosing-specific variants challenges polygenic risk modeling. Functional annotation lags behind association signals.
HLA-B27 Negative Case Heterogeneity
Prevalence and onset studies show HLA-B27 negative patients have delayed diagnosis and diverse phenotypes (Feldtkeller et al., 2003; Braun et al., 1998). Genetic markers for these cases remain elusive. Phenotyping inconsistencies confound GWAS power.
Essential Papers
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
Martín Rudwaleit, Désirée van der Heijde, R. B. M. Landewé et al. · 2009 · Annals of the Rheumatic Diseases · 3.5K citations
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S Smolen, D. Aletaha, J. W. J. Bijlsma et al. · 2010 · Annals of the Rheumatic Diseases · 2.0K citations
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
Martín Rudwaleit, D. van der Heijde, R. B. M. Landewé et al. · 2010 · Annals of the Rheumatic Diseases · 1.7K citations
Axial spondyloarthritis
Joachim Sieper, Denis Poddubnyy · 2017 · The Lancet · 1.3K citations
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Joseph M. Braun, Rosaline van den Berg, Xenofon Baraliakos et al. · 2011 · Annals of the Rheumatic Diseases · 978 citations
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors
J�rgen Braun, Mathias Bollow, Gerold Remlinger et al. · 1998 · Arthritis & Rheumatism · 913 citations
Objective To determine the overall prevalence of spondylarthropathy (SpA) among whites. Methods To screen for SpA symptoms, such as inflammatory back pain (IBP), joint swelling, psoriasis, and uvei...
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility
David M. Evans, Chris C. A. Spencer, Jennifer J. Pointon et al. · 2011 · Nature Genetics · 885 citations
Reading Guide
Foundational Papers
Start with Braun et al. (1998, 913 citations) for HLA-B27 prevalence baseline, then Rudwaleit et al. (2009, 3503 citations) for classification tying genetics to axial SpA diagnostics.
Recent Advances
Study Evans et al. (2011, 885 citations) for ERAP1 mechanisms and Cortés et al. (2013, 853 citations) for expanded loci; Sieper and Poddubnyy (2017, 1269 citations) contextualizes in axial SpA.
Core Methods
GWAS and high-density genotyping (Cortés et al., 2013); interaction modeling (Evans et al., 2011); population screening via questionnaires and HLA typing (Braun et al., 1998).
How PapersFlow Helps You Research HLA-B27 and Spondyloarthritis Genetics
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to trace HLA-B27 networks from Braun et al. (1998) to Evans et al. (2011), revealing 913+ citation clusters on prevalence and ERAP1 interactions. findSimilarPapers expands to related loci from Cortés et al. (2013); exaSearch queries 'HLA-B27 spondyloarthritis GWAS' for 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract HLA-B27 prevalence stats from Braun et al. (1998), then verifyResponse with CoVe checks genetic interaction claims against Evans et al. (2011). runPythonAnalysis computes odds ratios from GWAS tables in Cortés et al. (2013) using pandas; GRADE grading scores evidence strength for ERAP1 mechanisms as moderate.
Synthesize & Write
Synthesis Agent detects gaps in non-HLA markers post-Cortés et al. (2013), flags contradictions in HLA-B27 negative phenotypes (Feldtkeller et al., 2003). Writing Agent uses latexEditText for genetic pathway drafts, latexSyncCitations links Braun to recent citations, latexCompile builds reports; exportMermaid diagrams ERAP1-HLA-B27 interactions.
Use Cases
"Extract HLA-B27 prevalence odds ratios from Braun 1998 and recompute via Python."
Research Agent → searchPapers('Braun HLA-B27 spondyloarthritis') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas odds ratio calc) → CSV table of stratified risks.
"Draft LaTeX review on ERAP1-HLA-B27 with citations from Evans 2011."
Synthesis Agent → gap detection on peptide handling → Writing Agent → latexEditText('ERAP1 review') → latexSyncCitations(Evans) → latexCompile → PDF with synced refs.
"Find code for HLA-B27 GWAS simulations linked to Cortés 2013."
Research Agent → citationGraph(Cortés) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for polygenic risk modeling.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(HLA-B27 SpA genetics) → citationGraph → 50+ papers → structured report with GRADE scores on Evans (2011). DeepScan analyzes Braun (1998) in 7 steps: readPaperContent → verifyResponse → runPythonAnalysis(prevalence stats). Theorizer generates hypotheses on non-HLA loci from Cortés (2013) interactions.
Frequently Asked Questions
What defines HLA-B27's role in spondyloarthritis?
HLA-B27 is a strong genetic risk factor, with 5-8% prevalence in carriers developing spondyloarthropathy versus <1% in negatives (Braun et al., 1998). It associates with axial symptoms like inflammatory back pain.
What methods study these genetics?
Genome-wide association studies (GWAS) and high-density genotyping identify variants (Cortés et al., 2013). Interaction analyses probe ERAP1-HLA-B27 effects (Evans et al., 2011). Questionnaire screening assesses prevalence (Braun et al., 1998).
What are key papers?
Braun et al. (1998, 913 citations) quantifies HLA-B27 prevalence; Evans et al. (2011, 885 citations) details ERAP1 interactions; Cortés et al. (2013, 853 citations) lists multiple loci.
What open problems exist?
Mechanisms in HLA-B27 negative cases persist (Feldtkeller et al., 2003). Functional roles of non-MHC loci need validation. Polygenic scores for prognosis lack clinical integration.
Research Spondyloarthritis Studies and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HLA-B27 and Spondyloarthritis Genetics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers